Dapu Biotechnology and Leveragen Join Forces in Antibody Discovery
Dapu Biotechnology (DPBIO) and Leveragen, Inc. have announced a strategic partnership aimed at fostering innovation within the realm of antibody drug development. This collaboration signals a significant advancement for both companies as they leverage their unique strengths to tackle the challenges that have traditionally hampered antibody discovery processes.
Revolutionizing Antibody Development
With the integration of DPBIO’s Cytospark™ droplet microfluidic technology and Leveragen’s state-of-the-art Singularity Sapiens Mouse model, the initiative is set to redefine how therapeutic antibodies are developed. These technologies work in synergy to address the complex hurdles faced in modern antibody discovery, ensuring that the solutions they create are both effective and efficient.
Cytospark™ Technology Explained
The Cytospark™ platform is a groundbreaking tool that utilizes droplet microfluidics to encapsulate, analyze, and screen millions of single cells simultaneously. This capability drastically reduces the conventional timeline for antibody discovery, compressing what would normally take months into a mere 1–2 days. Such speed, coupled with precision, allows researchers to identify viable antibodies against previously challenging targets.
Leveragen’s Genetic Innovations
On the other hand, Leveragen's Singularity Sapiens Mouse is pioneering in the field, specifically designed to yield heavy-chain-only antibodies derived exclusively from a complete human immunoglobulin repertoire. By integrating this genetic framework into the mouse genome, it effectively sidesteps the limitations posed by traditional antibody models, paving the way for robust B cell development and enhanced immune responses. The resulting antibodies are not only highly diverse but also demonstrate superior affinity and stability, catering to a wide array of therapeutic applications.
A Commitment to Innovation
Dr. Xiaonan Xu, the Founder and CEO of Dapu Biotechnology, commented on the partnership, stating, "Cytospark™ has been engineered to revolutionize antibody discovery with unmatched speed and precision. Collaborating with Leveragen allows us to merge our complementary technologies to deliver flagship solutions that push the boundaries of therapeutic innovation."
Dr. Weisheng Chen, the CEO of Leveragen, echoed this sentiment, emphasizing that the partnership expands their antibody screening capabilities. "DPBIO's Cytospark™ technology redefines high-throughput functional antibody discovery, enhancing our research endeavors significantly,” Dr. Chen remarked. “Together, we can unlock new solutions for some of the healthcare sector's most challenging disease targets.”
Expanding Research Horizons
As part of their agreement, Dapu Biotechnology and Leveragen are set to tackle a complex therapeutic target that has often eluded conventional methods. Leveragen will maintain exclusive rights to the intellectual property associated with the antibodies produced during this collaboration, while DPBIO retains the right to utilize de-identified data to showcase its microfluidic technology capabilities.
This partnership exemplifies the commitment of both companies to not only advance antibody drug discovery but also to expedite the translation of these innovations into clinical settings, ultimately addressing pressing unmet medical needs.
About Dapu Biotechnology
Dapu Biotechnology, established in 2018, has emerged as a leader in droplet microfluidics. With a mission to deliver transformative solutions for life sciences and precision medicine, DPBIO operates research and manufacturing facilities in China. Their flagship offerings include the Cytospark™ High-throughput Screening System among others, which support various applications, including antibody screening and cancer research.
About Leveragen, Inc.
Headquartered in Boston, Leveragen specializes in creating advanced genetic models for antibody discovery. The company’s innovative Singularity Sapiens Mouse represents a leap forward in heavy-chain antibody generation, offering unparalleled diversity and functionality. With applications that span multiple therapeutic avenues, including multispecific antibodies and components for mRNA therapies, Leveragen is a trailblazer in the biotech space.
Frequently Asked Questions
What is the goal of the partnership between DPBIO and Leveragen?
The partnership aims to enhance antibody discovery through innovative technologies that address existing challenges in drug development.
What technology does DPBIO specialize in?
DPBIO specializes in droplet microfluidic technology, particularly the Cytospark™ platform designed for high-throughput antibody screening.
What unique features does the Singularity Sapiens Mouse offer?
Leveragen's mouse model generates heavy-chain-only antibodies from a complete human immunoglobulin repertoire, facilitating enhanced immune responses.
How does the Cytospark™ platform improve antibody discovery times?
The Cytospark™ platform significantly reduces the antibody discovery process from months to just 1-2 days through its high-throughput capabilities.
What are some applications of the technologies developed by these companies?
The technologies are applicable in various fields including cancer research, enzyme evolution, and the development of next-generation biologics and antibody therapeutics.
